-
公开(公告)号：US12247070B2
公开(公告)日：2025-03-11
申请号：US17418681
申请日：2019-12-26
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Bongcheol Kim , Dong Sik Kim , Jae-Keun Lee , Juwon Shim
Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat an atherosclerosis in a subject in need thereof.
-
2.发明授权公开(公告)号：US11746149B2
公开(公告)日：2023-09-05
申请号：US16626630
申请日：2018-06-27
Applicant: Neuracle Science Co., Ltd.
Inventor： Bongcheol Kim , Dong Sik Kim , Soon-gu Kwon
IPC: A61K39/395 , A61K39/00 , C07K16/24
CPC classification number: C07K16/24 , C07K2317/565 , C07K2317/622 , C07K2317/76
Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a glaucoma in a subject in need thereof.
-
公开(公告)号：US11634484B2
公开(公告)日：2023-04-25
申请号：US17050056
申请日：2019-04-24
Applicant: Neuracle Science Co., Ltd.
Inventor： Bongcheol Kim , Dong Sik Kim , Soon-Gu Kwon
Abstract: The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a KD of 10 nM or less, or binds to membrane bound human FAM19A5 with a KD of 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.
-
公开(公告)号：US12202889B2
公开(公告)日：2025-01-21
申请号：US17723149
申请日：2022-04-18
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Bongcheol Kim , Jae Young Seong , Jong Ik Hwang , Eun Bee Cho , Junho Chung , Junyeong Jin , Tae Young Yune , Jee Youn Lee
IPC: C07K16/18 , A61K39/00 , C07K7/00 , G01N33/563
Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.
-
公开(公告)号：US11970532B2
公开(公告)日：2024-04-30
申请号：US17054469
申请日：2019-05-10
Applicant: Neuracle Science Co., Ltd.
Inventor： Bongcheol Kim , Wonkyum Kim , Jeongwon Yoon , Junho Chung , Junyeong Jin , Eunhwoi You
IPC: C07K16/24 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/68 , A61P25/00 , A61P25/02 , A61P29/00 , A61P35/00
CPC classification number: C07K16/24 , A61K39/3955 , A61K45/06 , A61K47/6845 , A61P25/00 , A61P25/02 , A61P29/00 , A61P35/00 , A61K2039/505 , C07K2317/33 , C07K2317/41 , C07K2317/565 , C07K2317/622 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2317/74 , C07K2317/76 , C07K2317/92
Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.
-
Patent Agency Ranking
公开(公告)号：US11618783B2
公开(公告)日：2023-04-04
申请号：US16626624
申请日：2018-06-27
Applicant: Neuracle Science Co., Ltd.
Inventor： Bongcheol Kim , Jae-Keun Lee , Dong Sik Kim , Junho Chung , Junyeong Jin
IPC: C07K16/00 , A61K39/395 , C07K16/24 , A61P35/00 , G01N33/50 , G01N33/574 , A61K39/00
Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Also provided herein are methods for treating fibrosis or cancer using the anti-FAM19A5 antibodies.
-
公开(公告)号：US11155613B2
公开(公告)日：2021-10-26
申请号：US16626621
申请日：2018-06-27
Applicant: Neuracle Science Co., Ltd.
Inventor： Bongcheol Kim , Jae-Keun Lee , Dong Sik Kim
IPC: A61K39/00 , A61K39/395 , C07K16/24 , G01N33/68
Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.
-
公开(公告)号：US12077579B2
公开(公告)日：2024-09-03
申请号：US17475214
申请日：2021-09-14
Applicant: Neuracle Science Co., Ltd.
Inventor： Bongcheol Kim , Jae-Keun Lee , Dong Sik Kim
CPC classification number: C07K16/24 , G01N33/6863 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/76
Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.
-
公开(公告)号：US11560425B2
公开(公告)日：2023-01-24
申请号：US16626625
申请日：2018-06-27
Applicant: Neuracle Science Co., Ltd.
Inventor： Bongcheol Kim , Eun Bee Cho , Dong Sik Kim , Jae-Keun Lee , Soon-gu Kwon , Jae Young Seong , Juwon Shim , Tae Woo Kim , Shin-hyuk Kang
Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.
-
公开(公告)号：US11332521B2
公开(公告)日：2022-05-17
申请号：US16348058
申请日：2017-11-07
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Bongcheol Kim , Jae Young Seong , Jong Ik Hwang , Eun Bee Cho , Junho Chung , Junyeong Jin , Tae Young Yune , Jee Youn Lee
IPC: C07K16/18 , C07K7/00 , A61K39/00 , G01N33/563
Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.013 seconds)
